ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: Differentiating between these two conditions is clinically important since patients with ALK- ALCL typically have better overall survival and respond more favorably to Brentuximab vedotin compared to those with PTCL, NOS (8).